The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies
Open Access
- 1 November 2004
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 10 (5), 916-928
- https://doi.org/10.1016/j.ymthe.2004.07.022
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Human Nerve Growth Factor Receptor and Cytosine Deaminase Fusion GenesHuman Gene Therapy, 2003
- In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferaseGene Therapy, 2001
- Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectivesJournal of Cellular Physiology, 2001
- Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategyGene Therapy, 2000
- Experimental Gene Therapy for Brain Tumors Using Adenovirus-Mediated Transfer of Cytosine Deaminase Gene and Uracil Phosphoribosyltransferase Gene with 5-FluorocytosineHuman Gene Therapy, 2000
- Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.Radiation Research, 1999
- Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopyProceedings of the National Academy of Sciences of the United States of America, 1999
- Enzyme/Prodrug Therapy for Head and Neck Cancer Using a Catalytically Superior Cytosine DeaminaseHuman Gene Therapy, 1999
- Concomitant expression ofE. colicytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosineFEMS Microbiology Letters, 1998
- Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.Proceedings of the National Academy of Sciences, 1992